NCT05127421View on ClinicalTrials.gov

Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement

PHASE2CompletedINTERVENTIONAL

Enrollment

77

Participants

Timeline

Start Date

November 10, 2021

Primary Completion Date

August 3, 2023

Study Completion Date

September 29, 2023

Conditions

Atopic Dermatitis

Interventions

DRUG

Ruxolitinib cream

"Ruxolitinib cream 1.5% applied twice a day (BID)"

DRUG

Vehicle

Vehicle cream applied twice a day (BID) to affected areas

Trial Locations (1)

90230

Science37, Culver City

Sponsors

Lead Sponsor

Incyte Corporation

All Listed Sponsors

lead

Incyte Corporation

INDUSTRY